| Document |
Document Title |
|
WO/1998/007674 |
There are herein disclosed a difluorophenyl derivative compound having characteristics of a liquid crystal represented by general formula (1), a liquid crystal composition and a liquid crystal display device in which the composition is u...
|
|
WO/1998/005610 |
A process is disclosed for preparing fluorine-containing compounds by reacting a compound which contains a halogen that can be replaced by fluorine with a fluoride or a mixture of fluorides of general formula (I): MeF, in the presence of...
|
|
WO/1998/002409 |
The halogenation of a compound of formula (1) or formula (2'), wherein Q is an NH�2? group optionally in the form of an addition salt, or an NHCOCH�3? group, and X is a halogen atom, using a compound of formula X�2?, in a solvent s...
|
|
WO/1997/046534 |
The invention relates to a process for producing substituted aryl pyrazoles of general formula (I) in which R1, R2, R3 and R4 have the meanings given in the description, and novel intermediate products for producing said aryl pyrazoles.
|
|
WO/1997/045389 |
Disclosed is a method of making 1,2,4-trichlorobenzene. Dichlorobenzene containing less than an isomeric amount of meta-dichlorobenzene is isomerized to produce an isomeric mixture of dichlorobenzenes substantially rich in meta-dichlorob...
|
|
WO/1997/041083 |
Compounds containing a primary amino group are converted into compounds containing a fluorine atom in place of the amino group by reaction of the amino compound with hydrogen fluoride and a nitrosating reagent under the influence of ultr...
|
|
WO/1997/034855 |
Liquid crystalline compounds expressed by formula (1), liquid crystal compositions thereof obtained by combination with specified liquid crystal compounds, and liquid crystal display devices using them, wherein A1, A2, A3 and A4 denote e...
|
|
WO/1997/034589 |
The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted ...
|
|
WO/1997/032832 |
The production of fluorinated aromatic compounds of general formula (I), in which W, X, Z, R1 and R2 have the meanings given in the description, from corresponding C1 or Br-containing compounds with fluorides, e.g. KF, with halogen excha...
|
|
WO/1997/026237 |
Novel aromatic polycyclic retinoid-type derivatives of general formula (I), wherein groupings R3 and R4 attached to the double bond between carbons 11 and 12 are cis groupings, and pharmaceutical and cosmetic compositions containing same...
|
|
WO/1997/020877 |
Poly(bis-9,9'-fluorenes) are disclosed with identical or different recurring structural elements of formula (I), in which the two R1 groups independently of one another stand for H, C1-C18-alkyl, C6-C14-aryl, C7-C15-aralkyl, C1-C18-alkox...
|
|
WO/1997/018893 |
The present invention relates to a catalyst for preparing para-chloro aromatic compounds by the liquid-phase chlorination method. The catalyst is prepared by loading transition metal salts, rare earth metal salts or a mixture thereof, an...
|
|
WO/1997/016406 |
A compound of the formula (I): A-L-D where A is a moiety which absorbs radiation and enters an excited state in which it accepts an electron; L is a linking group which tethers an electron acceptor moiety A to the electron donor moiety D...
|
|
WO/1997/015541 |
Cyclic 'alpha'-perfluoro-di-p-xylylenes having the structure (I), wherein G is an aromatic nuclear substituent group selected from the group consisting of chlorine and fluorine (m = 4), and perfluoroalkyl groups having the formula CnF2n+...
|
|
WO/1997/013821 |
There are proposed liquid crystalline compounds expressed by formula (1) having high elastic constant ratio, low viscosity, stability as well as superior compatibility with other liquid crystalline compounds such as those expressed by ge...
|
|
WO/1997/010617 |
The invention concerns a photo-voltaic cell characterized in that it contains as the charge-transfer layer a perforated conductor material which preferably consists of an amorphous solid.
|
|
WO/1997/006124 |
Novel liquid-crystal compounds represented by general formula (1) and having a large value of permittivity anisotropy, a high voltage retention at service temperatures, a low threshold voltage, and improved compatibilities with other liq...
|
|
WO/1997/005184 |
The invention relates to 2,7-substituted-9-substituted fluorenes and 9-substituted fluorene oligomers and polymers. The fluorenes, oligomers and polymers are substituted at the 9-position with two hydrocarbyl moieties which may optionall...
|
|
WO/1997/002247 |
Disclosed are fluorinated phenanthrene derivatives of formula (I), in which the symbols and indices have the following meanings: E1, E2, E3, E4, E5 and E6 are identical or different and stand for -N-, -CF- or -CH-; G is -CF2CF2- or -CF=C...
|
|
WO/1996/041788 |
An object of the invention is to find out a promoter enabling the production of a 2,6-dichloro-3,5-di(secondary or tertiary alkyl)toluene of general formula (I) in a high yield without any restriction due to reaction scale. A 2,6-dichlor...
|
|
WO/1996/041787 |
Liquid crystal compounds being excellent in compatibility with other liquid crystal materials and stability and having a low viscosity and a high isotropic phase transition temperature; a liquid crystal composition containing at least on...
|
|
WO/1996/037451 |
A novel liquid crystalline compound having a large elastic constant ratio, excellent compatibility with other liquid crystalline compound(s) particularly at a low temperature, and chemical stability, or a liquid crystalline compound havi...
|
|
WO/1996/035664 |
New compounds have the formula (I), in which X stands for halogen, Y stands for halogen or alkyl and Z stands for halogen or alkyl, provided that one of the residues Y and Z always stands for halogen and the other for alkyl, and Het stan...
|
|
WO/1996/028403 |
Tetracyclic compounds having structure (1) are described, wherein R1-R10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovolatory e...
|
|
WO/1996/027584 |
An energy-sensitive (e.g., thermal, radiation or photosensitive) initiator, curative, and/or catalytic salt that has an anion comprising a tris-(highly fluorinated alkylsulfonyl)methide, tris-(fluorinated arylsulfonyl)methide, bis-(highl...
|
|
WO/1996/025376 |
4-Isobutylstyrene and other olefinic compounds corresponding to the formula C(R3)(R4)=C(R2)A are prepared by reacting an organic compound having the formula AX with a vinyl or substituted vinyl compound having the formula C(R3)(R4)=C(R2)...
|
|
WO/1996/015087 |
This invention relates to a novel process which comprises feeding a mixture formed from diphenylethane and bromine to a stirrable reaction mass comprised of bromine and a bromination catalyst to yield a decabromodiphenylethane wet cake w...
|
|
WO/1996/015096 |
Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula (T)xA-B-D-E-G, ...
|
|
WO/1996/013569 |
Disclosed is a single phase mixture of about 1 to about 99 wt% of a compound having general formula (I) where "n" is 1 or 2 and about 0.1 to about 99 wt% of a liquid which can be a perfluoro aliphatic alkane from C5 to C8, a perfluoro cy...
|
|
WO/1996/011227 |
A preferred process for producing a brominated, non-fused aromatic composition involves a continuous bromination in a continuous, mixed reactor such as a continuous stirred tank reactor. Bromine and the aromatic substrate, and optionaly ...
|
|
WO/1996/010003 |
The present invention relates to a novel process for preparing (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, also known in the art as (E)-(p-fluorophenethyl)-3-fluoroallylamine, novel intermediates thereof, a novel process fo...
|
|
WO/1996/009272 |
A tetracyclic chlorobenzene derivative represented by general formula (I) and being suitable for use in active-matrix display elements and a liquid-crystal composition containing the same (wherein each of rings A, B and C independently r...
|
|
WO/1996/008240 |
The present invention provides methods and product for inhibiting mammalian cell proliferation. Compounds that are anti-mycotics and that inhibit the Ca++-activated potassium channel of erythrocytes have been modified for use in the pres...
|
|
WO/1996/008457 |
This invention relates to a novel process which comprises feeding a mixture formed from diphenylethane and bromine to a stirrable reaction mass comprised of bromine and a bromination catalyst to yield a decabromodiphenylethane wet cake w...
|
|
WO/1996/006061 |
The invention relates to a novel and simple method for manufacturing laterally substituted chloroderivatives of formula (1) and 3,6-disubstituted cyclohex-2-en-1-ones being intermediates for their manufacturing. The chloroderivatives of ...
|
|
WO/1996/005159 |
A liquid crystal medium based on a mixture of polar compounds with positive dielectric anisotropy is characterised in that it contains one or several compounds having the general formula (I), in which R, A1, A2, Z1, Z2, Y, L1 and m have ...
|
|
WO/1996/003357 |
A process for the preparation of a selectively fluorinated organic compound, which process includes reaction of a precursor of said organic compound, the precursor containing at least one Group VI element selected from sulfur, selenium a...
|
|
WO/1996/003356 |
A method of iodinating and/or brominating and/or chlorinating an aromatic compound which comprises the steps of reacting an iodinating agent and/or brominating agent and/or chlorinating agent with the aromatic compound in the presence of...
|
|
WO/1996/001253 |
Certain compounds have been synthesized and found to be effective inhibitors of phospholipase A2 (PLA2), and thereby useful in the treatment of intestinal cholesterol absorption and the disease states arising therefrom, such as hyperchol...
|
|
WO/1996/000710 |
The invention describes liquid crystal compounds of formula (I) which are suitable for use in liquid crystal devices including those devices which exploit the electroclinic effect. The compounds of formula (I) may also be used as chiral ...
|
|
WO/1996/000208 |
Compounds have the general formula (I) Z[-Y1-(A-Y2)m-X]n, in which the variables have the following meanings: Z stands for an n-valent aliphatic residue with 2 to 20 C atoms or for an n-valent three to seven-membered saturated or unsatur...
|
|
WO/1995/035283 |
Compounds of general formula (1) are described, formula wherein =W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XRa group where X is -O-, -S(O)m- [where m is zero or an integer of value 1 or 2], or -N(Rb)- [where Rb is a hyd...
|
|
WO/1995/035281 |
Compounds of general formula (1) are described, wherein = W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl or -XRa group where X is -O-, -S(O)m- [where m is zero or an integer of value 1 or 2], or -N(Rb)- [where Rb is a hydrogen a...
|
|
WO/1995/032261 |
Fluoroalkyl ethinyl and difluoroalkyl ethinyl benzenes of formula (I) in which the symbols and indices have the following meanings: R1 is H, a straight chained or branched alkyl group (with or without an asymmetrical C atom) with 1 to 15...
|
|
WO/1995/030723 |
Supertwist liquid crystal displays with outstanding properties are obtained when the nematic liquid crystal mixture contains at least one compound of formula (I), where R1, R2, (a), p, r and s are as indicated in claim 1.
|
|
WO/1995/029886 |
The present invention concerns processes for preparing aromatic, bromine-containing compounds, novel bromine-containing compounds and their use as intermediate products in the synthesis of active agents. Processes according to the invent...
|
|
WO/1995/021817 |
A class of substituted spiro compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (III), wherein n is a number selected from 0, 1 and 2; where...
|
|
WO/1995/018848 |
The invention describes liquid crystal compounds of formula (I) which are suitable for use in liquid crystal devices including those devices which exploit the electroclinic effect, wherein X may be CN, NO2, CF3, CF2H, CFH2, halogen, hydr...
|
|
WO/1995/016658 |
Disclosed is a process for preparing allylic halides of the formula (I), wherein X is Cl, Br or I, for use as intermediates in the synthesis of substituted tetrahydrofuran azole anti-fungal agents.
|
|
WO/1995/016671 |
Methods of producing iodonium compounds by triflate-mediated iodonium transfer reactions are disclosed. Iodonium compounds sequester PQQ and inhibit PQQ-catalyzed cellular redox-cycling reactions involved in microbial metabolism and in h...
|
